This protocol addresses patients with submandibular gland cancer confirmed as secretory carcinoma harbouring an NTRK gene fusion, in the setting of recurrent or metastatic disease.
The presence of an NTRK gene fusion is the critical determinant for this treatment pathway. Molecular testing to confirm the fusion status is essential before selecting therapy in this setting.
The recommended strategy is targeted therapy directed at the TRK pathway. The complete specification of agents and the full structured regimen are available in the protocol below.
DOI: 10.1016/j.esmoop.2022.100602
In patients with secretory carcinoma and NTRK gene fusions, treatment with a TRK inhibitor (entrectinib or larotrectinib) is recommended [III, A; ESMO-Magnitude of Clinical Benefit Scale (MCBS) v1.1 score: 3; ESCAT score: I-C].
View source ↗